N/A
Completed N=75
Nociceptors, Neurotrophic Factors and Cytokine Expression in Gastroesophageal Reflux Disease
Gastro-esophageal Reflux Disease
Source: ClinicalTrials.gov NCT02114216 ↗
Enrolled (actual)
75
Serious AEs
—
Results posted
May 2016
Primary outcomePrimary: TRPV1, GDNF, and NGF mRNA Expression of Esophageal Mucosa — 1.14; 3.25; 2.33; 1.39 Fold change
Summary
Transient receptor potential vanilloid-1 (TRPV1) receptor and proteinase-activated receptor 2 (PAR2) have been implicated in the mechanism of acid induced inflammation in gastroesophageal reflux disease (GERD). We aimed to evaluate TRPV1 and PAR2 mRNA expression levels in the GERD patients and their relationship with endoscopic findings and reflux symptoms.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY TRPV1, GDNF, and NGF mRNA Expression of Esophageal Mucosa |
1.14; 3.25; 2.33; 1.39; 2.47; 2.05 | — |
| SECONDARY PAR2 and IL-8 Expression of Esophageal Mucosa |
1.37; 2.42; 2.29; 2.01; 4.36; 4.01 | — |
Eligibility Criteria
Inclusion Criteria
- subjects who completed upper GI endoscopy and questionnaires about GERD symptoms
Exclusion Criteria
- a history of gastrointestinal surgery
- Barrett's esophagus
- esophageal motility disorder
- duodenal ulcer
- benign gastric ulcer
- gastroduodenal cancer
- if he or she had any history of systemic disease requiring chronic medication (except for hypertension and diabetes mellitus).
Data sourced from ClinicalTrials.gov (NCT02114216). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.